NeuroXess’s CereCube system records up to 2048 neural signals simultaneously and stimulates 128 electrode sites. It captures local field potentials, single-neuron spikes, and electrocorticogram signals.
NeuroXess developed the FlexShuttle Mini, an intelligent surgical robot for precise neuroscience research on mice and rats. It automates surgeries, supports flexible and rigid electrodes, and enables procedures like optogenetics.
With fully independent, end-to-end R&D capabilities, NeuroXess leverages its globally leading flexible BCI technologies and engineering expertise to provide advanced tools and integrated system solutions for scientific research and clinical applications.
NeuroXess, founded in 2021, develops implantable flexible BCIs to help patients with ALS, high paraplegia, stroke, and other neurological disorders restore motor and language functions.
NeuroXess secures **RMB 700 million** in Series B funding from SDIC Juli, Shenzhen Capital Group, and Qinzhi Capital. The company develops **implantable brain-computer interfaces** combining flexible electrodes with wireless power and data transmission, enabling movement, speech decoding, and external device control. NeuroXess has completed **65 clinical cases**, launched a **multi-hospital registration trial**, and is constructing a **14,300 sqm manufacturing facility** with an annual capacity of **10,000 systems**.
